Overall verdict
Neutral
4.4/10
1-year performance
-4.73%
Score breakdown
Down 4.7% over 1 year, 5% of the 52-week range.
14 analysts, target +2.3% vs the price.
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing, manufacturing, and selling of genetic therapies for rare and devastating diseases in the United States. It develops in vivo adeno-associated viral (AAV) programs, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to heart failure (RP-A501), which is in Phase 2 trial ;
Plakophilin-2 Arrhythmogenic Cardiomyopathy (PKP2-ACM), an inheritable cardiac disorder that is characterized by a progressive loss of cardiac muscle mass, severe right ventricular dilation, dysplasia, fibrofatty replacement of the myocardium and a high propensity to arrhythmias and sudden death (RP-A601), which is in phase 1 ; and BAG3 Dilated Cardiomyopathy (BAG3-DCM), which is a form of cardiomyopathy and is characterized by progressive thinning of the walls of the heart, which is in preclinical stage.
It also develops ex vivo lentiviral (LV) programs, which include programs for Leukocyte Adhesion Deficiency-I (LAD-I), a genetic disorder that causes the immune system to malfunction (RP-L201) ; Fanconi Anemia (FA), a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells (RP-L102) ; and Pyruvate Kinase Deficiency (PKD), a red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia (RP-L301).
It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red de Enfermedades Raras, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz ; UCL Business PLC ; The Regents of the University of California ; and Temple University. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.
Sector
Health Care
Industry
Biotechnology
Primary listing
Nasdaq
United States
CEO
Gaurav Shah
Founded
1999
Employees
202
Revenue / employee
0 USD
Next earnings
November 6, 2026 (estimated)
Institutional holders
- RTW INVESTMENTS, LP14.64%
- BlackRock, Inc.8.05%
- VANGUARD PORTFOLIO MANAGEMENT LLC4.71%
- CITIGROUP INC3.95%
- MARSHALL WACE, LLP3.27%
- MILLENNIUM MANAGEMENT LLC3.25%
- Newtyn Management, LLC3.25%
- MAVERICK CAPITAL LTD3.18%
- VANGUARD CAPITAL MANAGEMENT LLC3.07%
- Other institutions34.64%
- Rest of the register18.00%
181 13F filings as of June 30, 2026: US managers above $100M, filed up to 45 days after quarter end. No insiders, no retail. A share on loan is declared by its lender and by whoever bought it from the short seller, so the total can exceed 100%.
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
5.45 USD
52-week low
2.53 USD
1-year performance
-4.73%
Declining
Year-to-date performance
-13.96%
Declining
Drawdown
-50.64%
Major drawdown
Position in the 52-week range
5% of range
ROIC -4.5%, ROE -4.8%.
Net margin
—
Sector -229.23%|S&P 12.97%
Gross margin
—
Return on equity (ROE)
-4.77%
Negative
Sector -58.37%|S&P 16.52%
Return on invested capital (ROIC)
-4.50%
Negative
Free cash flow margin (FCF)
—
Revenue (trailing 12 months)
0 USD
Revenue growth (1y)
—
Revenue growth (3y)
—
EPS growth (1y)
—
EPS CAGR (5y)
—
EPS revisions (3 months)
—
Valuation
0.0/10The company loses money, so no valuation multiple can be read: a negative P/E is not a discount.
P/E (TTM)
—
N/A (loss)
Sector 11.3x|S&P 23.0x
Forward P/E (adjusted)
—
EV / EBITDA
—
N/A (loss)
Sector 13.4x|S&P 14.5x
PEG
—
Sector 0.12|S&P 0.86
Market cap
332M USD
Financial strength
5.8/10Cash covers 1144.2% of the debt, no net debt (net cash).
Net debt / EBITDA
—
Gearing (net debt / equity)
-70.21%
Net cash
Cash
284M USD
Cash / market cap
85.59%
Very solid
Cash / total debt
1144.23%
Net cash
Interest coverage
-101.3x
Stretched
Net debt
-259M USD
Equity
369M USD
Closed daily candles, 2 years
Last close on September 24, 2026: 2.69 USD
- MM203.51
- MM503.45
- MM2003.59
- RSI 1428.1
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
+1.08%
200-day average slope, 3 months
+1.33%
50-day average slope, 1 month
-0.38%
Price structure
higher-low
Bullish RSI divergence
No
20-day volatility
4.14 % per day
Volatility change
+1.13%
Forecasts by fiscal year
| Fiscal year | EPS | Normalised EPS | Revenue | EBITDA | Net income |
|---|---|---|---|---|---|
| 2026 | -0.28 (12) | -0.11 (4) | 1 (12) | -182 (3) | -18 (10) |
| 2027 | -1.39 (11) | -1.30 (5) | 11 (12) | -199 (3) | -182 (10) |
Amounts in millions of USD, EPS in USD per share. In brackets, the number of analysts. Consensus as of September 16, 2026.
Same sub-industry: 734 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | CUV | 6.5 | 6.3 | 294M USD | 12.4x | 36.1 % | -1.0 % | 13.2 % | -6.0x | 8.3 % | -29.0 % | ||
| 2 | XFOR | 4.9 | 2.5 | 308M USD | Not meaningful (loss) | -568.8 % | 346.3 % | -57.6 % | 1.5x | — | -13.3 % | ||
| 3 | IKT | 4.4 | 0.9 | 300M USD | Not meaningful (loss) | — | — | -52.0 % | 2.4x | -14.2 % | 29.6 % | ||
| 4 | CATX | 4.4 | 1.6 | 299M USD | Not meaningful (loss) | -28516.1 % | -72.1 % | -39.2 % | 2.1x | -40.6 % | -21.4 % | ||
| 5 | RCKT | 4.4 | N/A | 332M USD | Not meaningful (loss) | — | — | -4.5 % | — | -51.4 % | -4.7 % | ||
| 6 | SANN | 4.0 | 3.5 | 286M USD | Not meaningful (loss) | -63.8 % | 97.3 % | -62.8 % | -2.3x | -15.4 % | 25.2 % | ||
| 7 | ALERS | 3.6 | 4.1 | 287M USD | 51.9x | 2.9 % | 9.1 % | 2.6 % | -0.1x | 1.9 % | -1.4 % | ||
| 8 | AMRN | 3.3 | 3.7 | 290M USD | Not meaningful (loss) | -14.6 % | -42.6 % | -5.9 % | 14.7x | 5.4 % | -12.0 % | ||
| 9 | A174900 | 2.1 | 2.2 | 285M USD | Not meaningful (loss) | -328.3 % | 51.4 % | -40.6 % | 0.2x | -3.1 % | 27.3 % |
